Rock Springs Capital Management LP Allakos Inc. Transaction History

Rock Springs Capital Management LP

$2.94 Billion
Q3 2024

A detailed history of Rock Springs Capital Management LP transactions in Allakos Inc. stock. As of the latest transaction made, Rock Springs Capital Management LP holds 1,200,409 shares of ALLK stock, worth $1.16 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares

1,200,409

Previous 1,200,409 -0.0%

Holding current value

$1.16 Million

Previous $1.2 Million 35.0%

% of portfolio

0.03%

Previous 0.04%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$1.0 - $1.45 $1.2 Million - $1.74 Million	1,200,409 New	1,200,409 $1.2 Million
Q4 2021 Feb 14, 2022	SELL	$8.55 - $111.89 $2.61 Million - $34.2 Million	-305,706 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$109.73 - $153.66 $3.93 Million - $5.5 Million	-35,794 Reduced 10.48%	305,706 $35.1 Million
Q4 2020 Feb 16, 2021	BUY	$79.58 - $152.45 $7.95 Million - $15.2 Million	99,918 Added 41.36%	341,500 $47.8 Million
Q3 2020 Nov 16, 2020	BUY	$66.43 - $90.99 $169,396 - $232,024	2,550 Added 1.07%	241,582 $19.7 Million
Q2 2020 Aug 14, 2020	BUY	$44.04 - $80.69 $177,569 - $325,342	4,032 Added 1.72%	239,032 $17.2 Million
Q4 2019 Feb 14, 2020	SELL	$66.49 - $137.73 $3.66 Million - $7.58 Million	-55,000 Reduced 18.97%	235,000 $22.4 Million
Q3 2019 Nov 14, 2019	SELL	$31.0 - $89.73 $3.53 Million - $10.2 Million	-114,000 Reduced 28.22%	290,000 $22.8 Million
Q4 2018 Feb 14, 2019	SELL	$31.59 - $62.65 $31,590 - $62,650	-1,000 Reduced 0.25%	404,000 $21.1 Million
Q3 2018 Nov 14, 2018	BUY	$31.25 - $47.64 $12.7 Million - $19.3 Million	405,000 New	405,000 $18.2 Million

Others Institutions Holding ALLK

# of Institutions

Shares Held

64.7M

Call Options Held

47.1K

Put Options Held

View Full List

About Allakos Inc.

Ticker ALLK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,726,096
Market Cap $82.2M
Description
Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and...

More about ALLK

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rock Springs Capital Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Rock Springs Capital Management LP with notifications on news.

Account

Rock Springs Capital Management LP Allakos Inc. Transaction History